Huiyu Pharmaceutical's paclitaxel injection plans to be included in priority review

On December 25, CDE official website showed that Huiyu pharmaceutical's Paclitaxel injection was proposed to be included in the priority review for the reason that "the same production line has been listed in EU countries in 2019 and applied for domestic listing" According to the sales system of pharmaceutical intelligence data hospital, the sales volume of paclitaxel in 2018 was 823 million yuan, an increase of 83.68% year on year Paclitaxel injection for the national medical insurance category a drug intelligence data shows that there are 42 domestic enterprises with the production approval of this variety At present, Paclitaxel injection has not been evaluated by any enterprise, only one enterprise in Yangzi River has submitted an application for conformity evaluation Huiyu pharmaceutical has applied for production of new 4 categories of chemicals If it is approved successfully, it will be deemed to have passed the conformity evaluation Data source: This article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.